Incyte Corporation (INCY) News
Filter INCY News Items
INCY News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest INCY News From Around the Web
Below are the latest news stories about Incyte Corp that investors may wish to consider to help them evaluate INCY as an investment opportunity.
Lilly’s anti-inflammatory drug Olumiant reduced hospital stays when combined with Gilead’s remdesivir.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
INDIANAPOLIS, Sept. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the…
Gilead Sciences drew mixed reactions from analysts after the company announced its largest acquisition ever, gaining a possible flagship cancer treatment. GILD stock rose on the news.
Eli Lilly and Incyte released positive initial data of their coronavirus treatment when combined with Gilead's remdesivir and said they would seek emergency use authorization from the FDA.
FEATURE Here’s what you need to know about the impact of Covid-19 to navigate the markets today. • This year’s Macy’s Thanksgiving Day Parade will be a TV-only event, with in-person viewing discouraged and big changes to the procession.
Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time
Eli Lily & Co. and Incyte Corp. said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.'s remdesivir. Shares of Lily gained 0.7% in premarket trading on Monday, while Incyte's stock was up 1.4% and shares of Gilead were down 2.1%. The Food and Drug Administration (FDA) earlier this year authorized remdesivir as a treatment for some hospitalized COVID-19 patients, though the drug has not received a full approval at this time. A number of clinical trials are underway that are testing remdesivir in combination with other therapies, including Olumiant. The Phase 3, double-blind, randomized, controlled study testing Olumiant and remdesivir in 1,000 patients was...
Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuity Award, an annual program that was created to support people living with graft-versus-host disease (GVHD) by encouraging innovative and novel solutions that address specific challenges facing the GVHD community. Massachusetts General Cancer Center has been awarded $100,000 to implement its project, Horizon Mobile App for Patients with Chr
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM